0001193125-16-774365.txt : 20161122 0001193125-16-774365.hdr.sgml : 20161122 20161122073802 ACCESSION NUMBER: 0001193125-16-774365 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161118 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20161122 DATE AS OF CHANGE: 20161122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 162011719 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 d299427d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2016

 

 

ENANTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35839   04-3205099

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

500 Arsenal Street, Watertown, Massachusetts 02472

(Address of principal executive offices and zip code)

(617) 607-0800

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

Appointment of Lesley Russell to Board of Directors

On November 18, 2016, the Board of Directors of Enanta Pharmaceuticals, Inc. appointed Lesley Russell, MBChB, MRCP to serve as an independent director of the Company in the class of directors whose terms expire at Enanta’s 2019 Annual Meeting of Stockholders. The Board of Directors also appointed Dr. Russell as a member of the Audit and Nominating and Corporate Governance Committees of the Board of Directors, effective as of January 1, 2017.

Dr. Russell will receive the standard compensation for non-employee directors of Enanta, including retainer fees for Board and committee service and stock options, and will have the benefit of the Company’s standard form of indemnification agreement.

Pending Retirement of Ernst-Günter Afting from the Board of Directors

Dr. Ernst-Günter Afting has advised the Board that he will retire as an independent director of Enanta, effective as of the 2017 annual meeting of stockholders. Dr. Afting’s retirement is not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices.

In addition to his service on Enanta’s Board of Directors, Dr. Afting served as a member of the Board’s Audit Committee and its Nominating and Corporate Governance Committee.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 22, 2016   ENANTA PHARMACEUTICALS, INC.
  By:   

/s/ Paul J. Mellett

    Paul J. Mellett
    Senior Vice President, Finance and Administration and Chief Financial Officer